MMCM
REGN icon

Murphy & Mullick Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Murphy & Mullick Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Sell
240
-36
-13% -$24.5K 0.09% 165
2026
Q1 		$213K Sell
276
-5
-2% -$3.83K 0.16% 131
2025
Q4 		$217K Sell
281
-79
-22% -$53.6K 0.16% 131
2025
Q3 		$202K Sell
360
-14
-4% -$7.92K 0.15% 133
2025
Q2 		$204K Sell
374
-56
-13% -$31.3K 0.17% 129
2025
Q1 		$273K Sell
430
-14
-3% -$9.63K 0.26% 89
2024
Q4 		$316K Buy
+444
New +$373K 0.29% 80

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Murphy & Mullick Capital Management's REGN Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2026, selling an estimated $24.5K and leaving 240 shares worth $150K. The position accounts for 0.09% of the portfolio, ranked #165.

Murphy & Mullick Capital Management first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $316K in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Murphy & Mullick Capital Management held 240 shares of Regeneron Pharmaceuticals worth $150K as of Q2 2026.
  • Murphy & Mullick Capital Management sold 36 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $24.5K.
  • Regeneron Pharmaceuticals made up 0.09% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #165 holding.
  • Murphy & Mullick Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Murphy & Mullick Capital Management's Regeneron Pharmaceuticals position peaked at $316K in Q4 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.